BUND FINANCE › Stocks › AMGN
Amgen Inc. (AMGN)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +3.93% above its 50-day average.
- It is +16.15% above its 200-day average (long-term uptrend).
- It sits at 77% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$26.0B | US$26.3B | US$28.2B | US$33.4B | US$36.7B |
| Net income | US$5.9B | US$6.6B | US$6.7B | US$4.1B | US$7.7B |
| EPS (diluted) | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 |
| Gross margin | 75.2% | 75.7% | 70.2% | 61.5% | 70.8% |
| Operating margin | 29.4% | 36.3% | 28.0% | 21.7% | 29.1% |
| Net margin | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| Free cash flow | US$8.4B | US$8.8B | US$7.4B | US$10.4B | US$8.1B |
| Total debt | US$33.3B | US$38.9B | US$64.6B | US$60.1B | US$54.6B |
| Cash | US$8.0B | US$7.6B | US$10.9B | US$12.0B | US$9.1B |
Compound annual growth: revenue 9.1% · net income 7.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 25.8x | 24.7x | 27.1x |
| EV / EBITDA | 15.5x | 13.8x | 16.5x |
| Operating margin | 35.5% | — | 3.6% |
| Net margin | 24.1% | — | -0.0% |
| Debt / equity | 5.69 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infectio…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice